Jakafi (ruxolitinib) is not chemotherapy. It is a targeted therapy, specifically a kinase inhibitor that blocks specific proteins driving disease. This distinction matters because Jakafi works through a fundamentally different mechanism than traditional chemotherapy, and the experience of taking it is quite different from what most people picture when they hear “chemo.”
How Jakafi Differs From Chemotherapy
Traditional chemotherapy drugs work by attacking rapidly dividing cells throughout the body. They don’t distinguish well between cancer cells and healthy cells, which is why they cause widespread side effects like hair loss, severe nausea, and damage to the gut lining. Chemotherapy is often delivered through an IV in a clinical setting over hours at a time.
Jakafi takes a targeted approach. It’s a pill you take at home, twice daily, with or without food. It comes in tablet form (5 mg to 25 mg strengths) and doesn’t require infusions or visits to a treatment center for administration. There’s no association with hair loss in clinical trials, and the side effect profile looks nothing like traditional chemo.
How Jakafi Actually Works
Jakafi blocks two specific enzymes called JAK1 and JAK2. These enzymes are part of a signaling pathway that tells blood cells to grow and that regulates inflammation. In conditions like myelofibrosis, a mutation causes JAK2 signaling to get stuck in the “on” position, driving the overproduction of abnormal blood cells and triggering chronic inflammation.
By inhibiting JAK2, Jakafi helps control that overproduction of blood cells and reduces spleen enlargement, which is a major source of discomfort in myelofibrosis. By inhibiting JAK1, it dials down inflammatory signals throughout the body. This is why patients often notice improvements in symptoms like night sweats, fatigue, and bone pain. The drug works on both the normal and mutated forms of JAK2, so it affects the disease pathway broadly rather than targeting only mutated cells.
What Jakafi Treats
The FDA first approved Jakafi in 2011 for intermediate or high-risk myelofibrosis, a blood cancer where scar tissue builds up in the bone marrow and disrupts normal blood cell production. This includes primary myelofibrosis as well as myelofibrosis that develops after polycythemia vera or essential thrombocythemia.
Since then, Jakafi has also been approved for polycythemia vera (when a previous treatment hasn’t worked well enough) and for certain forms of graft-versus-host disease, a complication that can occur after a stem cell transplant. It remains the most widely used JAK inhibitor worldwide for these conditions.
Side Effects Compared to Chemo
The side effects of Jakafi reflect its targeted mechanism. You won’t experience the hallmark chemotherapy effects like hair loss, mouth sores, or severe vomiting. Instead, the most common mild side effects include dizziness, headache, fatigue, weight gain, swelling from fluid retention, digestive issues like gas or diarrhea, and muscle pain or spasms.
The more serious side effects involve changes to blood cell counts. Because Jakafi affects the signaling pathways that regulate blood cell production, it can cause anemia (low red blood cells), thrombocytopenia (low platelets, which affects clotting), and neutropenia (low white blood cells, which affects infection defense). These are monitored through regular blood tests. If platelet counts drop too low, your dose may be reduced or temporarily paused until counts recover. This is different from chemotherapy-induced drops in blood counts, which tend to be more severe and harder to manage with simple dose adjustments.
Infection risk is another consideration. Jakafi can increase susceptibility to certain infections, including opportunistic infections, because of its effect on immune signaling. This is worth tracking but is a more specific and manageable risk than the broad immune suppression caused by chemotherapy.
Why the Confusion Exists
Jakafi is prescribed by oncologists, used to treat blood cancers, and can affect blood cell counts, so it’s understandable why people wonder if it’s chemotherapy. The term “chemotherapy” is sometimes used loosely to mean any cancer drug, but in medical classification, Jakafi falls into the targeted therapy category. Targeted therapies zero in on specific molecular pathways driving a disease, while chemotherapy broadly attacks cell division.
This distinction has practical implications. If you’re starting Jakafi and worried about losing your hair, needing IV infusions, or spending hours in a treatment chair, those aren’t part of the experience. You’ll take a tablet at home and have regular blood work to make sure your counts stay in a safe range. Some people stay on Jakafi for years. If the drug is providing benefit in controlling symptoms or spleen size, treatment generally continues. Doctors reassess if the disease progresses, side effects become intolerable, or the drug stops working effectively.